Lineage Cell Therapeutics, Inc.
LCTX
$1.27
$0.0958.12%
AMEX
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | 10.91M | 9.56M | 9.50M | 8.72M | 6.19M |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 10.91M | 9.56M | 9.50M | 8.72M | 6.19M |
Cost of Revenue | 12.91M | 12.68M | 12.66M | 13.25M | 13.95M |
Gross Profit | -2.00M | -3.12M | -3.16M | -4.53M | -7.76M |
SG&A Expenses | 18.23M | 18.03M | 18.17M | 14.53M | 14.16M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 31.31M | 30.88M | 30.98M | 27.92M | 28.25M |
Operating Income | -20.40M | -21.32M | -21.48M | -19.20M | -22.07M |
Income Before Tax | -40.76M | -16.17M | -18.58M | -20.05M | -24.20M |
Income Tax Expenses | -- | -- | -- | 0.00 | 0.00 |
Earnings from Continuing Operations | -40.76 | -16.17 | -18.58 | -20.05 | -24.20 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -152.00K | -39.00K | -27.00K | -65.00K | 16.00K |
Net Income | -40.91M | -16.21M | -18.61M | -20.11M | -24.19M |
EBIT | -20.40M | -21.32M | -21.48M | -19.20M | -22.07M |
EBITDA | -19.77M | -20.72M | -20.87M | -18.57M | -21.40M |
EPS Basic | -0.18 | -0.08 | -0.10 | -0.11 | -0.13 |
Normalized Basic EPS | -0.07 | -0.05 | -0.06 | -0.06 | -0.07 |
EPS Diluted | -0.18 | -0.08 | -0.10 | -0.11 | -0.13 |
Normalized Diluted EPS | -0.07 | -0.05 | -0.06 | -0.06 | -0.07 |
Average Basic Shares Outstanding | 883.44M | 843.89M | 800.75M | 735.57M | 721.60M |
Average Diluted Shares Outstanding | 883.44M | 843.89M | 800.75M | 735.57M | 721.60M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |